Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy
2016 · Annals of Oncology · 161 citations
https://doi.org/10.1093/annonc/mdw228